The art and science of outcomes analysis, quality improvement, and patient safety continue to evolve, and cardiothoracic surgery leads many of these advances. The Society of Thoracic Surgeons (STS) National Database is one of the principal reasons for this leadership role, as it provides a platform for the generation of knowledge in all of these domains. Understanding these topics is a professional responsibility of all cardiothoracic surgeons. Therefore, beginning in January 2016, The Annals of Thoracic Surgery began publishing a monthly series of scholarly articles on outcomes analysis, quality improvement, and patient safety. This article provides a summary of the status of the STS National Database as of October 2016 and summarizes the articles about the STS National Database that appeared in The Annals of Thoracic Surgery 2016 series, "Outcomes Analysis, Quality Improvement, and Patient Safety." (Ann Thorac Surg 2016;102:1790-7) Ó 2016 by The Society of Thoracic Surgeons T he art and science of outcomes analysis, quality improvement, and patient safety continue to evolve at an increasingly rapid pace, and cardiothoracic surgery leads many of these advances. The Society of Thoracic Surgeons (STS) National Database is one of the principal reasons for this leadership role, as it provides a platform for the generation of important new knowledge in all of these domains. To better care for patients and to be successful in today's rapidly evolving health care environment, understanding these topics is an essential professional responsibility of all cardiothoracic surgeons. Therefore, beginning in January 2016, The Annals of Thoracic Surgery began publishing a monthly series of scholarly articles on outcomes analysis, quality improvement, and patient safety [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] .
The STS National Database has three major component databases: the STS Adult Cardiac Surgery Database (ACSD), the STS Congenital Heart Surgery Database (CHSD), and the STS General Thoracic Surgery Database (GTSD). In 2016, six of the articles that appeared in The Annals of Thoracic Surgery 2016 series, "Outcomes Analysis, Quality Improvement, and Patient Safety" were derived from the STS National Database [2, 4, 6, 8, 10, 12] : three articles on outcomes and quality (one each from ACSD, CHSD, and GTSD) [2, 4, 6] , and three articles on research (one each from ACSD, CHSD, and GTSD) [8, 10, 12] . These six articles alternated with five additional articles on topics related to patient safety [3, 5, 7, 9, 11] . The purpose of this final article in the 2016 series is to provide a summary of the status of the STS National Database as of October 2016 and to summarize the articles from this series that were derived from the STS National Database.
The STS National Database-Outcomes and Quality
The STS National Database captures outcomes data from 90% to 95% of the adult cardiac surgery programs in the United States of America and more than 95% of the pediatric cardiac surgery programs in the United States of America. The penetration of the STS GTSD cannot be calculated because the number of general thoracic surgical programs in the United States of America (the denominator of penetration) is not known. (Figure 3 in the report by Jacobs and colleagues [1] provides graphs documenting the number of participants [the numerator of penetration; Fig 3A] and surgeons [ Fig 3B] in the STS GTSD.) Table 1 of this article provides information about the size and penetrance of the three major component databases of the STS National Database [13, 14] .
A fundamental function of the STS National Database is to provide feedback reports to participants that allow individual programs to benchmark their outcomes to national aggregate data. Each quarter, participants in the STS ACSD receive detailed feedback reports of their practice characteristics, including demographics, risk factor profiles, operative data, and outcomes, c An STS database participant is a "practice group of cardiothoracic surgeons" or, uncommonly, an individual cardiothoracic surgeon. In most instances, an STS database participant is a hospital cardiac or thoracic surgery program.
d In most situations, 1 STS database participant is linked to 1 hospital; however, in some instances, 1 STS database participant is linked to more than 1 hospital or 1 hospital is linked to more than 1 STS database participant. Therefore, the number of STS database participants and the number of hospitals is slightly different.
e Total number of operations in the STS ACSD refers to the total number of operations captured in the STS ACSD since its formation in 1989. The total number of operations in the STS CHSD and GTSD refers to the total number of operations in the CHSD and GTSD since these databases began storing data at Duke Clinical Research Institute (DCRI) in 1998. DCRI is the data warehouse and analytic center for ACSD, CHSD, and GTSD.
f Center-level penetration (number of CMS sites with at least 1 matched STS participant divided by the total number of CMS CABG sites) increased from 45% in 2000 to 90% in 2012. In 2012, 973 of 1,081 CMS CABG sites (90%) were linked to an STS site. Patient-level penetration (number of CMS CABG hospitalizations done at STS sites divided by the total number of CMS CABG hospitalizations) increased from 51% in 2000 to 94% in 2012. In 2012, 71,634 of 76,072 CMS CABG hospitalizations (94%) occurred at an STS site. Completeness of case inclusion at STS sites (number of CMS CABG cases at STS sites linked to STS records divided by the total number of CMS CABG cases at STS sites) increased from 88% in 2000 to 98% in 2012. In 2012, 69,213 of 70,932 CMS CABG hospitalizations at STS sites (97%) were linked to an STS record [13] .
g The 2015 STS Congenital Heart Surgery Practice and Manpower Survey estimates that 125 hospitals perform pediatric cardiac surgery in the United States and 8 hospitals perform pediatric cardiac surgery in Canada [14] .
h The penetration of the STS GTSD cannot be calculated because the number of general thoracic surgical programs in the USA (the denominator of penetration) is not known. benchmarked against the STS national aggregate data. Similar detailed feedback reports are provided to the STS CHSD and GTSD participants every 6 months. Selected national aggregate outcomes of the more commonly performed surgical procedures in the STS ACSD, CHSD, and GTSD are provided in Tables 2, 3 , and 4, respectively [2, 4, 6, 15, 16] .
The ultimate goal of all database activities is to improve patient outcomes. The leadership of the STS in the areas of quality measurement and quality improvement is demonstrated by the commitment of STS to obtain endorsement for all its performance measures by the National Quality Forum (NQF). The NQF is a multistakeholder, nonprofit, membership-based organization that aims to improve the quality of health care through the preferential use of only the most valid performance measures. An NQF endorsement is the gold standard for health care quality measures, and NQFendorsed measures are recognized by the national health care community as "best in class," evidence-based, and valid. The STS has developed 34 quality measures that are endorsed by the NQF [1] . A detailed listing of these 34 performance measures has been previously published [1] , and Table 5 stratifies these quality measures by the Donabedian triad of structure, process, and outcome. The STS is currently the steward for more (1) all deaths, regardless of cause, occurring during the hospitalization in which the operation was performed, even if after 30 days (including patients transferred to other acute care facilities); and (2) all deaths, regardless of cause, occurring after discharge from the hospital but before the end of postoperative day 30 [15, 16] .
c National Quality Forum definition of reoperation. NQF-endorsed measures than any other specialty-based medical professional organization [1] . Table 6 lists STS NQF projects in which STS's measures currently are being reviewed for endorsement. In addition to reviewing five previously endorsed STS measures, NQF is considering several new STS composite measures, including an individual surgeon composite measure for adult cardiac surgery [17] , a composite score for mitral valve repair/ replacement [18] , and a composite score for mitral valve repair/replacement combined with coronary artery bypass grafting (CABG) [19] . Finally, because of its commitment to accountability and transparency, the STS publicly reports cardiac surgical outcomes on both the Consumer Reports Web site and the STS Web site (http://www.sts.org/qualityresearch-patient-safety/sts-public-reporting-online). 
The STS National Database-Research
Summaries of research based on each of the three STS National Databases were published in 2016 [8, 10, 12] . STS has recently expanded its research enterprise by putting into operation the new STS Participant User File Research Program, which allows, for the first time, analysis of national-scale deidentified data from the STS National Database at investigators' institutions. The Participant User File Research Program creates a platform where clinical outcomes and comparative effectiveness research using the STS data can be done at investigators' own institutions. This program is unique in many respects and was designed primarily as an affordable option for investigators to pose research questions, quickly obtain quality data, analyze these data themselves given appropriate biostatistics resources, receive feedback, and develop their efforts into abstracts and manuscripts. For additional information about the STS Participant User File, please visit: http://www.sts.org/sites/default/files/ documents/pdf/Abridged-PUF-ProgramDescription_FINAL. pdf?_cldee¼dmthcnRoYTFAamhtaS51ZHU%3d&recipientid ¼contact-a0c64a844ce946adade00af70dc53add-9b5f0e32b08e4 b24b1766bababd4106d.
As the STS Research Centers grow, efforts are ongoing to obtain extramural funding for research using the STS (1) all deaths, regardless of cause, occurring during the hospitalization in which the operation was performed, even if after 30 days (including patients transferred to other acute care facilities); and (2) all deaths, regardless of cause, occurring after discharge from the hospital, but before the end of postoperative day 30 [15, 16] . We hypothesize individual cardiac, inflammatory, and renal biomarkers can identify patients at high risk of readmission or death within 30 days after adult cardiac surgery. We will evaluate the ability of novel biomarkers of cardiac injury (ST2, BNP, cTnT), renal injury (cystatin C), and inflammation (galectin-3, interleukin-6 [IL-6]) to predict 30-day readmission or death using banked blood from 2,500 TRIBE cardiac surgery patients. We will obtain complete ascertainment of readmission and death by linking TRIBE to Medicare claims, state and provincial all-payer claims, STS data within each center, chart review, and the National Death Index (NDI). We will include 100 noncardiac elective surgery controls from Johns Hopkins. 1b. We hypothesize that a multimarker panel can improve our ability to identify patients with a high risk of readmission or death within 30 days after cardiac surgery compared with clinical factors alone. We will test the ability of biomarkers to improve prediction of 30-day readmission or death and develop new parsimonious models. We will assess model improvement with biomarkers using novel statistical methods (net reclassification index). Aim 2. Evaluate the ability of novel biomarkers to identify children with an increased risk of 30-day readmission or death after pediatric congenital heart surgery. 2a. We hypothesize individual cardiac, inflammatory, and renal biomarkers can identify children at high risk of death or readmission within 30 days after congenital heart surgery. We will measure novel biomarkers including BNP, cTnT, cystatin C, ST2, galectin-3, brain injury (glial fibrillary acidic protein [GFAP]), and inflammatory cytokine panel (MSD Human TH1/TH2 10-Plex) from 500 children in TRIBE to determine risk of 30-day readmission or death. We will link TRIBE to state claims, STS data, and the NDI for readmission and death. We will include 100 pediatric controls from Dr Everett at Johns Hopkins. 2b. We hypothesize a multimarker panel can improve our ability to identify children with high risk of death or readmission within 30 days after congenital heart surgery. Similar methods in 1b will be applied. Aim 3. Externally validate biomarker models for readmission or death. 3a. Adult Model Validation. We will externally validate our perioperative prediction model of 30-day readmission or death using banked serum from 1,800 NNE cardiac surgery patients from 8 medical centers. We will measure the same biomarkers in Aim 1 and externally validate the clinical plus multimarker model from Aim 1b using NNE clinical and biomarker data. We will obtain complete readmission and death end points by links to Medicare and state all-payer claims, STS, chart review, and the NDI. 3b. Congenital Model Validation. We will externally validate our prediction of 30-day mortality and readmission among children in the TRIBE congenital heart surgery cohort using 294 children from the Johns Hopkins congenital heart surgery cohort. We will measure biomarkers in Aim 2 and methods in Aim 3a.
(Continued) To design and conduct a "trial within a registry" to evaluate safety and efficacy of perioperative steroids for neonatal CPB. Doing so, we will develop the infrastructure for a registry-based pediatric heart surgery trials network and define a new model for cost-effective clinical trials that can be used to study other understudied diseases and conditions. SPECIFIC AIMS: Aim 1. Use Monte Carlo simulations based on registry data to design a high yield, low cost trial. Hypothesis: The optimal trial will enroll high-risk neonates with a composite morbidity/mortality primary end point. Aim 2. Conduct a "trial within a registry" of methylprednisolone in neonates undergoing CPB. Hypothesis: Methylprednisolone will decrease mortality/major morbidity and reduce hospital length of stay. Aim 3. Demonstrate cost savings and efficiency of our approach in neonates with CHD. Hypothesis: Compared with a traditional trial approach, this trial will reduce cost per patient enrolled by 70% and exceed time to completion of final enrollment by 30%. SUMMARY: This trial will be the largest ever in neonates with CHD, will be conducted at a fraction of the cost of a traditional trial, and will answer a clinical question that has persisted for decades. Upon completion, we will have established the infrastructure for a national registry-based trials network in children undergoing heart surgery. Moreover, our approach will serve as a model for other understudied diseases and conditions. National Database. Table 7 lists four active R01 research grants and one active U01 research grant involving the STS National Database. The U01 is unique in that it is the first STS grant to implement a "trial within a registry" approach to conducting a prospective randomized clinical trial, with the STS CHSD also serving as the primary registry for the randomized clinical trial.
